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Several recent cardiovascular outcome trials (CVOT) in patients with type 2 diabetes 
have shown benefit in terms of both weight loss and cardiovascular benefit. At the same 
time a number of epidemiological studies have shown that a body mass index above 25 
kg/m2 may be beneficial - the so-called ‘obesity paradox’. We discuss whether these 
CVOT support the potential benefits of intentional or therapeutic weight loss, but 
conclude that such conclusions would be simplistic and will require trials specifically 
designed for this purpose. 
 
Abbreviations: 
CVOT: Cardiovascular outcome trial 
CV: Cardiovascular 
T2DM: Type 2 diabetes mellitus 
GLP-1: Glucagon like peptide -1 
SGLT2: Sodium-glucose co-transporter 2 
CAD: coronary artery disease 
CHF: chronic heart failure 
BMI: Body mass index 
COPD: chronic obstructive pulmonary disease 
SCOUT: Sibutramine Cardiovascular Outcomes 
FDA: Food and Drugs Administration 
LEADER: Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results 
EMPA-REG: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 
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Recent cardiovascular (CV) outcome trials of treatments for type 2 diabetes mellitus 
(T2DM) including Glucagon like peptide -1 (GLP-1) receptor agonists1,2 and Sodium-
glucose co-transporter-2 (SGLT2) inhibitor3 have shown beneficial effects on both CV 
outcomes and body weight. The so-called ‘obesity paradox’ refers to the 
epidemiological inference that obesity, defined by a body mass index (BMI) >30 kg/m2, 
when compared to normal weight (probably incorrectly defined as a BMI of 18.5-25 
kg/m2), is associated with ‘counterintuitive improved health in a variety of disease 
conditions, including cardiovascular disease’? 4 Do the trial findings further undermine 
the belief in a paradox, and can they provide support for the benefits of intentional 
weight loss? 
 
Obesity and cardiovascular disease 
Obesity is a major modifiable cardiovascular risk factor for secondary prevention in 
coronary artery disease (CAD).5 As a direct risk factor, obesity initiates several 
pathophysiological pathways such as ‘reducing insulin sensitivity, enhancing free fatty 
acid turnover, increasing basal sympathetic tone, inducing a hypercoagulable state, and 
promoting systemic inflammation’6 that contribute to the development and progression 
of CAD. Indirectly, obesity is a risk factor for the development of T2DM, 
dyslipidaemia, hypertension, and obstructive sleep apnoea,7,8 all of which are 
‘cardiovascular risk factors in their own right’.9 Obesity is associated with an increased 
mortality as a result of the maladaptive effects of the aforementioned risk factors.10 The 
incidence and prevalence of both obesity and chronic heart failure (CHF) are rising, so 
that it is increasingly likely that the two conditions may co-exist in a patient,11 15–37% 
of CHF patients are obese.12,13,14 
 
‘The obesity paradox’ 
Reverse epidemiology infers that apparent risk factors such as obesity confer 
advantageous short and long-term prognosis.4  An inverse relationship between obesity 
and cardiovascular mortality has been described in several studies with patients with 
coronary heart disease,9,15,16 hypertension,17 percutaneous revascularisation,10 and 
coronary artery bypass grafting.10 Furthermore, Angeras and colleagues reported a ‘U-
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shape relationship between mortality and body mass index (BMI) in patients with acute 
coronary syndromes’,4 consistent with the findings of Kapoor et al.18 A meta-analysis 
of six studies (n=22,807) on the relationship between BMI and all-cause mortality, 
cardiovascular mortality and hospitalisation in patients with CHF found the risk for 
cardiovascular mortality and hospitalisation was highest in the underweight and lowest 
in the overweight.19 
 
The source of the paradox has posed much debate in the literature. Some take the view 
that there is no paradox because the basis for defining an ‘ideal’, ‘healthy’ or ‘normal’ 
reference BMI of 18.5-25 kg/m2 has no basis.20,21 BMI also fails to account for 
variations in lifetime weight history,22 body composition,23 fat distribution24,25 or 
physical or cardio-respiratory fitness.26 
 
 
Two prominent schools of thought seek to explain the association. Firstly, it is proposed 
that there are properties and biological pathways within the obese phenotype that 
provide cardiovascular protection and increased prognostic value.27 Secondly, causal 
inference from observational studies is statistically fraught, and that the association is 
coincidental due to study limitations and/or lack of adjustment for confounding factors 
in overweight and obese cohorts. 
 
Heysmfield and colleagues suggest that adipose tissue may provide energy reserve 
during acute illnesses.27 Direct cardioprotective effects such as a reduction in infarct 
size have been observed in individuals with excess adiposity during myocardial 
infarction.27 It has been speculated that the ‘anti-inflammatory, anti-apoptotic and anti-
hypertrophic characteristics’28 of hormones such as leptin and adiponectin released 
from adipose tissue are the cause of such effects.29 Furthermore, cardioprotection in 
CHF has been supported by the work of Mehra and colleagues.30  
 
Contrarily, it has been argued that these paradoxical findings may represent an 
epiphenomenon rather than a true causal relationship due to limitations of the studies 
in which they are presented. There is evidence of strong confounding by variables such 
as smoking and statistical adjustment for smoking is often insufficient.31 Smokers tend 
to be leaner than non-smokers and the intensity of smoking is related to both BMI and 
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mortality.31 Past and current smokers should be excluded from studies to ensure there 
are no confounding effects.31  
 
Additionally, patients with obesity may be subject to aggressive secondary preventions 
such as treatment for T2DM, hypertension and cholesterol, all of which may manifest 
as cardioprotection.32 Medical intervention and administration of medication earlier on 
in the stage of disease may be advantageous in obese patients and thus must be adjusted 
for.33,34  
 
Reverse causation and the impact of disease on weight must also be addressed, as 
underlying disease states may result in unintentional weight loss and long-term 
sequalae of poor prognosis. Studies should exclude deaths from a set number of years 
after follow-up to reduce the effect of reverse causality, however, chronic conditions 
such as heart failure, chronic lung disease and depression may not have received clinical 
diagnosis and thus results must be critiqued with this in mind.31  
 
Martin-Ponce and colleagues, speculate that their results, which favoured individuals 
whom were overweight and obese, were influenced by patient characteristics rather 
than ‘specific beneficial effect of excess fat’35 – i.e. selection or collider bias.36,37 They 
observed that obese patients were ‘younger, had better nutritional status and suffered 
less from sepsis, chronic obstructive pulmonary disease (COPD) and dementia’34 (all 
of which have been classified as high mortality diseases). After conducting a 
multivariate analysis, they noted that obesity did not show an independent predictive 
value when assessed with short and long-term survival.  
 
 
The effects of weight loss  
Many observational studies and randomised trials show that weight loss markedly 
improves cardiovascular risk factors including blood pressure, lipids and glycaemia.38 
Furthermore, most evidence, but not all,4,39 shows that moderate (intentional) weight 
loss, including those with T2DM, reduces mortality.40,41,42 Even in the Sibutramine 
Cardiovascular Outcomes (SCOUT) trial, those who lost weight saw a 6.80% absolute 
risk reduction for primary outcome of cardiovascular events.43  At the same time, 
weight gain has been linked to a worsening of such cardiovascular risk factors.31 
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It is evident that conflicting results surround epidemiological studies, and thus the 
significance of intentional versus unintentional weight loss cannot be underestimated. 
One can speculate that contradictory results are ‘perhaps due to confounding of 
unintentional weight loss’44, a notion supported by Sorenson and colleagues.39 
 
Weight and Body Mass Index (BMI)  
The limitations of BMI in discriminating between adipose tissue and lean mass are well 
documented.9 Specifically, patients with cardiovascular disease with static or increased 
lean mass are associated with better cardiorespiratory fitness and thus better 
prognosis.45 Individuals may be classified as ‘metabolically healthy but obese 
phenotype’46 and skew a favourable outcome.9 Sarcopaenia and sarcopaenic obesity in 
contrast are associated with worse CV outcomes, so potentially biasing against a 
population with lower BMI.47 Studies demonstrating the paradoxical association do not 
‘typically adjust BMI for other measures of adiposity’ such as waist circumference, 
waist to hip ratio and body fat percentage.11  
 
Diabetes Mellitus- Evaluating Cardiovascular Risk in New Antidiabetic Therapies to 
Treat T2DM  
As a complex metabolic disorder, T2DM is characterised by hyperglycaemia and 
‘associated with a high risk of cardiovascular, microvascular, and other 
complications.’1 Obesity is a documented risk factor for T2DM,48 however, T2DM can 
be induced in the absence of obesity in those with ‘greater genetic susceptibility’.49 In 
such cases, T2DM is more likely to develop ‘at a lower BMI “stress”50, with greater 
risk for comorbidities and poor prognosis.48  
 
In 2008, following concerns surrounding therapeutic induced adverse cardiovascular 
effects,49 the Food and Drug Administration (FDA) released guidance for the 
pharmacological industry on the development of new anti-diabetic therapies,51 driving 
large randomised cardiovascular outcome trials (CVOT) during drug development. 
Drugs from two classes of hypoglycaemic drugs, both of which are associated with 
reductions in body weight, have now reported favourable cardiovascular outcomes.  
Can such trials inform about the potential benefit or harm for weight loss in generally 
high-risk patients (with T2DM)? 
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Sodium-Glucose Co-transporter 2 Inhibitor (SGLT2i) (empagliflozin) 
In the EMPA-REG OUTCOME study, empagliflozin, when added to standard care in 
patients at high CV risk significantly reduced the primary composite outcome (i.e. CV 
death, nonfatal myocardial infarction or stroke) and all-cause death as well as a 30-40% 
lower hospitalization for heart failure.3 Mean BMI at baseline was >30 kg/m2; benefit 
for the primary outcome and for cardiovascular death was confined to those with a BMI 
<30 kg/m2. Alongside significant metabolic and blood pressure improvement, weight 
was reduced by about 2 kg. 
 
Glucagon-like peptide-1 receptor agonists (GLP-1) (liraglutide and semaglutide) 
Liraglutide is a once-daily human GLP-1 receptor analogue approved for the treatment 
of T2DM (at a dose of up to 1.8 mg/day) and chronic weight management (at 3.0 
mg/day).52,53,54,55 In the Liraglutide Effect and Action in Diabetes: Evaluation of 
Cardiovascular Outcome Results (LEADER) double blind trial of liraglutide, 1.8 mg 
subjects had a mean BMI of 32.5 kg/m2.1 Placebo-subtracted weight loss was 2.3 kg in 
the liraglutide group. In contrast to EMPA-REG, the benefit in composite primary 
outcome was confined to those with a BMI >30kg/m2.3 
 
Semaglutide, a GLP-1 analogue with an extended half-life of approximately 1 week 
allowing once-weekly subcutaneous administration, was also evaluated in a CVOT 
(SUSTAIN-6) in which the primary composite outcome was the first occurrence of 
cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.2 At two years 
mean body weight in the semaglutide group, as compared with the placebo group, was 
2.9 kg lower in the group receiving 0.5 mg and 4.3 kg lower in the group receiving 1.0 
mg. CV benefit was significant in those with a BMI  30 kg/m2.   
 
Relevance to the ‘obesity paradox’ and potential benefits of weight loss 
All three of these trials were designed to demonstrate the safety of the individual drugs 
in patients with T2DM. They were not weight-loss trials, and the populations studied 
heterogeneous in terms of age, weight, BMI as well as cardiovascular morbidity, co-
medication. None of the trials included dietary or exercise advice for weight loss. 
Specific mechanisms by which the drugs induced weight loss likely differed: to 
  8 
simplify, GLP-1 agonism has direct effects on suppressing hunger56 while SGLT2i 
produce obligatory energy losses from increased urinary glucose excretion as well as a 
modest osmotic diuresis,57 although these may be offset by metabolic adaptations.58 
Additionally, both drugs have the potential for cardioprotection over and above 
improved glycaemia.59,60,61,62 Finally, the CV benefit differed between trials as to 
whether it was the obese or non-obese who derived significant benefit.   
 
Conclusion  
The LEADER, SUSTAIN-6 and EMPA-REG trials undoubtedly demonstrate that 
GLP-1 agonists and/or SGLT2i  provide a therapeutic option for individuals at high risk 
of cardiovascular events with T2DM that enables robust control of glucose, weight 
reduction and major cardiovascular event (MACE) outcome risk reduction.1,2,3 While 
post-hoc analyses of these trials might allow further hypotheses to be generated 
concerning the possible contribution of weight loss to the effects seen, specific 
cardiovascular outcome trials will be needed to further explore the relevance of weight 
loss.  Such trials should better phenotype the trial population for their obesity, although 
quantitating fat (and ideally lean) mass and its distribution will be problematic for such 
large trials. ‘The obesity paradox’ is a complex phenomenon. The reconciliation of such 
paradoxical associations requires inherent statistical limitations of clinical studies to be 
addressed, consistent utilisation of more accurate measurements of adiposity, and better 
understanding of the underlying mechanisms of obesity, T2DM, incretin-related drugs 
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